Goldman Sachs initiated coverage of MiniMed (MMED) with a Buy rating and $67 price target representing 67% upside potential. The firm believes the shares are giving “little-to-no credit” for MiniMed’s pipeline. The company’s pipeline is already tracking ahead of expectations, the analyst tells investors in a research note. Goldman believes MiniMed has a “compelling risk/reward” at current share levels.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMED: